Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial
Identifieur interne : 000416 ( Istex/Curation ); précédent : 000415; suivant : 000417Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial
Auteurs : Jacques Montplaisir [Canada] ; Jeff Karrasch [Australie] ; Jean Haan [Allemagne] ; Dieter Volc [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-10.
English descriptors
- KwdEn :
Abstract
The objective of this study was to investigate the long‐term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single‐blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double‐blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double‐blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression–Improvement (CGI‐I) scale, change in International Restless Legs Scale (IRLS) score during double‐blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI‐I scores, sleep and QoL parameters with single‐blind ropinirole, which were better maintained when ropinirole was continued during the double‐blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long‐term management of RLS, with pharmacological effect over 36 weeks. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21050
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000416
Links to Exploration step
ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation wicri:level="1"><mods:affiliation>Hôpital du Sacré‐Coeur de Montréal, Montréal, Quebec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Hôpital du Sacré‐Coeur de Montréal, Montréal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
<affiliation wicri:level="1"><mods:affiliation>Peninsula Clinical Research Centre, Kipparing, Queensland, Australia</mods:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Peninsula Clinical Research Centre, Kipparing, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
<affiliation wicri:level="1"><mods:affiliation>Neurologische Klinik, Schlafmedizinisches Zentrum, Moenchengladbach, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Neurologische Klinik, Schlafmedizinisches Zentrum, Moenchengladbach</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
<affiliation wicri:level="1"><mods:affiliation>Confraternitaet–Privatklinik, Josefstadt, Wien, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Confraternitaet–Privatklinik, Josefstadt, Wien</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21050</idno>
<idno type="url">https://api.istex.fr/document/ECEA56C61D08B8B6730CC0CD43272110B95065F9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000416</idno>
<idno type="wicri:Area/Istex/Curation">000416</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation wicri:level="1"><mods:affiliation>Hôpital du Sacré‐Coeur de Montréal, Montréal, Quebec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Hôpital du Sacré‐Coeur de Montréal, Montréal, Quebec</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
<affiliation wicri:level="1"><mods:affiliation>Peninsula Clinical Research Centre, Kipparing, Queensland, Australia</mods:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Peninsula Clinical Research Centre, Kipparing, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
<affiliation wicri:level="1"><mods:affiliation>Neurologische Klinik, Schlafmedizinisches Zentrum, Moenchengladbach, Germany</mods:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Neurologische Klinik, Schlafmedizinisches Zentrum, Moenchengladbach</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
<affiliation wicri:level="1"><mods:affiliation>Confraternitaet–Privatklinik, Josefstadt, Wien, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Confraternitaet–Privatklinik, Josefstadt, Wien</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-10">2006-10</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">10</biblScope>
<biblScope unit="page" from="1627">1627</biblScope>
<biblScope unit="page" to="1635">1635</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">ECEA56C61D08B8B6730CC0CD43272110B95065F9</idno>
<idno type="DOI">10.1002/mds.21050</idno>
<idno type="ArticleID">MDS21050</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>long‐term management</term>
<term>randomized controlled clinical trial</term>
<term>restless legs syndrome</term>
<term>ropinirole</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate the long‐term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single‐blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double‐blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double‐blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression–Improvement (CGI‐I) scale, change in International Restless Legs Scale (IRLS) score during double‐blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI‐I scores, sleep and QoL parameters with single‐blind ropinirole, which were better maintained when ropinirole was continued during the double‐blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long‐term management of RLS, with pharmacological effect over 36 weeks. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000416 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000416 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:ECEA56C61D08B8B6730CC0CD43272110B95065F9 |texte= Ropinirole is effective in the long‐term management of restless legs syndrome: A randomized controlled trial }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |